Start-Up Quarterly Statistics, Q1 2014
This article was originally published in Start Up
Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.
You may also be interested in...
Tesaro has plans to bring an anti-PD-1 agent into the clinic by mid-2015, with other immunotherapies to follow. The compounds will be products of AnaptysBio’s proprietary antibody platform.
Moderna Therapeutics says it has found ways to design, manufacture, formulate, and deliver mRNA so that it can instruct cells in different tissues and organs to make virtually any protein, intracellular or secreted. To begin commercializing drugs designed to make therapeutic proteins inside patients' own cells, Moderna has spun out Onkaido Therapeutics Inc. and funded it with $20 million and 15 oncology drug candidates, in the areas of apoptosis, central regulatory nodes, and immunotherapy.
Placing assets in new companies is a growing trend for biotech start-ups; freed to evolve differently, spin-outs are structured to increase exit options and maximize investor returns. We profile Envisia Therapeutics, F-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics.